CDH16 and oncocytic neoplasm: Whether some of the novel oncocytic and molecularly defined RCC subtypes (eosinophilic vacuolated tumour, low-grade oncocytic tumour and TFE3-rearranged, TFEB-altered, ELOC (formerly TCEB1)-mutated, fumarate hydratase-deficient, succinate dehydrogenase-deficient, ALK-rearranged renal cell carcinomas and SMARCB1-deficient renal medullary carcinoma)—which were not distinguished in our historic tumor collection—may be particularly linked to CDH16 negativity needs to be determined in further studies.